15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $55M | -$164M | 100.0% | -253.7% | -182.6% | -58.5% | -$209M | — | $15M |
| 2024 | $98M | -$119M | 68.8% | -106.9% | -195.9% | -39.2% | -$177M | — | $44M |
| 2023 | $90M | -$276M | 62.5% | -292.6% | -210.7% | -69.3% | -$193M | — | $35M |
| 2022 | $92M | -$368M | 76.5% | -408.6% | -100.4% | -51.8% | -$310M | — | $88M |
| 2021 | $102M | -$524M | 75.6% | -437.8% | -77.1% | -46.9% | -$428M | — | $25M |
| 2020 | $153M | -$444M | 87.3% | -278.0% | -41.3% | -28.9% | -$321M | — | $199M |
| 2019 | $115M | -$441M | 81.4% | -383.9% | -31.4% | -22.3% | -$355M | — | $96M |
| 2018 | $1.2B | $681M | 98.0% | 57.6% | 39.7% | 31.7% | $704M | — | $195M |
| 2017 | $308M | -$97M | 90.1% | -19.4% | -110.1% | -19.0% | -$90M | — | $5M |
| 2016 | $165M | -$154M | 81.7% | -68.2% | -174.2% | -27.0% | -$123M | — | $60M |
| 2015 | — | -$81M | — | — | -1262.7% | -16.3% | — | — | $56M |
| 2014 | — | -$54M | — | — | -148.4% | -12.2% | — | — | $12M |
| 2013 | — | -$162M | — | — | 180.2% | -37.3% | -$43M | — | $39M |
| 2012 | — | -$172M | — | — | -365.5% | -34.5% | -$140M | — | $25M |
| 2011 | — | -$134M | — | — | -67.7% | -22.1% | -$123M | — | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $10M | -$41M | 0.0% | -417.9% | -4.5% | -3.7% | -$76M | — | $39M |
| Mar '26 | $11M | -$45M | 0.0% | -359.6% | -7.8% | -5.9% | -$44M | — | $150M |
| Dec '25 | $22M | -$36M | 100.0% | -126.9% | -40.2% | -12.9% | -$65M | — | $15M |
| Sep '25 | $12M | -$36M | 100.0% | -268.6% | -41.7% | -11.8% | -$49M | — | $41M |
| Jun '25 | $11M | -$42M | 100.0% | -324.2% | 171.8% | -20.0% | -$46M | — | $43M |
| Mar '25 | $10M | -$51M | 100.0% | -425.8% | -370.4% | -19.9% | -$49M | — | $39M |
| Dec '24 | $29M | $7M | 72.7% | 49.2% | 12.0% | 2.4% | -$47M | — | $44M |
| Sep '24 | $24M | -$37M | 81.6% | -142.4% | -75.8% | -12.0% | -$45M | — | $30M |
| Jun '24 | $23M | -$52M | 58.5% | -211.9% | -65.7% | -15.3% | -$38M | — | $28M |
| Mar '24 | $22M | -$37M | 60.6% | -163.7% | -29.0% | -9.3% | -$48M | — | $49M |
| Dec '23 | $24M | -$42M | 69.5% | -140.3% | -32.1% | -10.6% | -$47M | — | $35M |
| Sep '23 | $24M | -$46M | 48.5% | -185.8% | -28.8% | -10.4% | -$42M | — | $65M |
| Jun '23 | $20M | -$51M | 65.9% | -246.8% | -26.0% | -10.3% | -$52M | — | $51M |
| Mar '23 | $22M | -$137M | 67.3% | -623.8% | -56.9% | -24.4% | -$52M | — | $77M |
| Dec '22 | $22M | -$60M | 71.7% | -238.2% | -16.3% | -8.4% | -$58M | — | $88M |
| Sep '22 | $24M | -$59M | 79.0% | -229.8% | -14.3% | -7.6% | -$83M | — | $106M |
| Jun '22 | $22M | -$159M | 76.3% | -708.1% | -34.7% | -18.5% | -$76M | — | $78M |
| Mar '22 | $25M | -$90M | 78.6% | -469.6% | -14.9% | -8.8% | -$93M | — | $68M |
| Dec '21 | $25M | -$146M | 75.4% | -451.5% | -21.4% | -13.0% | -$157M | — | $25M |
| Sep '21 | $25M | -$130M | 78.7% | -455.8% | -16.2% | -10.2% | -$104M | — | $54M |
How the market has priced NKTR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Nektar Therapeutics's revenue has declined 18.4% per year. These are computed facts, not advice.
As of FY2025, Nektar Therapeutics reported — of total debt against $15M of cash.
In FY2025, gross margin was 100.0%, operating margin -253.7%, and net margin -296.9%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.